Potential pitfalls in reading medical articles for primary care physicians;Lecture d'articles médicaux: Quelques pièges à éviter

Revue Medicale Suisse

Volumn 3, Issue 135, 2007, Pages 2718-2723

  Rodondi, Nicolas ^a   Cornuz, Jacques ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TORCETRAPIB;

CLINICAL PRACTICE; HUMAN; MEDICAL ERROR; MEDICAL LITERATURE; PHYSICIAN; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; REVIEW; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CLINICAL TRIALS AS TOPIC; DEMENTIA; EARLY DIAGNOSIS; EDUCATION, MEDICAL, CONTINUING; HUMANS; HYPERCHOLESTEROLEMIA; LUNG NEOPLASMS; ODDS RATIO; PERIODICALS AS TOPIC; PHYSICIANS, FAMILY; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; READING; RISK FACTORS;

EID: 37149054554     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage 1 lung cancer detected on CT screening. N Engl J Med 2006;355:1763-71.
2. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart study) : Case-control study. Lancet 2004;364:937-52.
3. Butler J, Rodondi N, Zhu Y, et al. Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol 2006;47:1595-602.
4. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med 1999;340:618-26.
5. Schwartz LM, Woloshin S, Welch HG. Misunderstandings about the effects of race and sex on physicians' referrals for cardiac catheterization. N Engl J Med 1999;341:279-83; discussion 286-7.
6. Zhang J, Yu KF. What's the relative risk ? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:1690-1.
7. Schwartz LM, Woloshin S, Dvorin EL, Welch HG. Ratio measures in leading medical journals : Structured review of accessibility of underlying absolute risks. BMJ 2006;333:1248.
8. Rodondi N, Peng T, Karter AJ, et al. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med 2006;144:475-84.
9. Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N, Newman TB. Designing clinical research : An epidemiologic approach. 2nd ed. Philadelphia : Lippincott Williams & Wilkins, 2001.
10. Fleming TR, DeMets DL. Surrogate end points in clinical trials : Are we being misled ? Ann Intern Med 1996;125:605-13.
11. Fleming TR. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 2005;24:67-78.
12. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD : A 6-month randomized, placebo-controlled trial with a 6-month extension. The galantamine USA-1 study group. Neurology 2000;54:2261-8.
13. Birks J, Grimley Evans J, lakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000.CD001191.
14. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2003:CD001190.
15. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet 2004;363:2105-15.
16. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16.
17. Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 2007;356:1364-6.
18. Cornuz J, Guessous I, Rodondi N. Primary prevention and screening in adult : Update 2006. Rev Med Suisse 2006;2:262-73.
19. Bach PB, Jett JR, Pastorino U, et al. Computed tomography screening and lung cancer outcomes. JAMA 2007;297:953-61.
20. Black WC, Baron JA. CT screening for lung cancer : Spiraling into confusion ? JAMA 2007;297:995-7.
21. Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the mayo lung project : Impact of extended follow-up. J Natl Cancer Inst 2000;92:1308-16.
22. Goldberg P. Lung screening advocates say verdict's in, attack NCl randomized trial as «outdated». Cancer Lett 2006;32:1-7.
23. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007;356:2522-4.
24. Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999;282:786-90.